Emmaus Life Sciences (EMMA) AI Stock Analysis

89 Followers

Emmaus Life Sciences

(Other OTC:EMMA)

Select Model

Rating:37Underperform

Price Target:$0.01▼(-39.13% Downside)

Action:reiterated

Date:11/13/26

Emmaus Life Sciences receives the minimum possible overall score, primarily driven by critical insolvency risks, severe balance sheet distress, and a massive equity deficit. The stock is technically devastated, trading well below all major moving averages with strong downward momentum, and its valuation is entirely unsupported due to persistent net losses. While recent trailing-twelve-month cash flow showed a positive inflection, it is heavily overshadowed by the company's overwhelming debt burden and extremely fragile financial footing.

Positive Factors

Revenue and gross-margin strengthStrong recent revenue growth combined with consistently high gross margins indicates that Endari sales can support substantial gross profit when demand is present. This provides funding potential for commercialization and development, although continued growth is needed to translate product economics into sustainable earnings.

Negative Factors

Negative equity and elevated debtPersistently negative equity leaves the company with a thin financial cushion and reduces flexibility to absorb operating setbacks. Debt of roughly $30–33M adds refinancing pressure, while the weak equity base may increase dependence on dilution or other external financing to meet obligations.

Emmaus Life Sciences (EMMA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.61M
Dividend Yield: ―
Average Volume (3M): 153.31K
Price to Earnings (P/E): -0.2
Beta (1Y): -1.03
Revenue Growth: 10.98%
EPS Growth: -72.08%
Country: US
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Emmaus Life Sciences Business Overview & Revenue Model

Company Description

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and...

How the Company Makes Money

Emmaus Life Sciences has historically generated revenue primarily from product sales of Endari (L-glutamine oral powder) for sickle cell disease. Revenue is generally recognized when product is sold and delivered to customers (e.g., wholesalers/speci...

Emmaus Life Sciences Financial Statement Overview

Summary

Assigned the lowest possible score due to severe balance sheet distress, shrinking assets, and a massive equity deficit of -$66.2 million. While there was a recent positive turn in operating cash flow and EBITDA, persistent historical unprofitability and overwhelming debt present critical insolvency risks.

Income Statement

35Negative

Balance Sheet

10Very Negative

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Jun 2024	Dec 2022	Mar 2022
Income Statement
Total Revenue	15.53M	12.45M	16.65M	29.60M	18.39M	20.61M
Gross Profit	14.54M	11.60M	15.45M	28.25M	15.80M	17.30M
EBITDA	3.40M	-310.00K	-910.00K	3.62M	-5.50M	-12.76M
Net Income	-6.02M	-7.49M	-6.45M	-3.73M	-10.63M	-15.95M
Balance Sheet
Total Assets	16.37M	21.44M	23.60M	35.18M	48.23M	56.73M
Cash, Cash Equivalents and Short-Term Investments	2.81M	2.13M	1.39M	2.55M	2.02M	2.28M
Total Debt	30.52M	32.56M	32.96M	32.65M	30.82M	29.91M
Total Liabilities	82.55M	85.04M	80.08M	82.94M	82.32M	78.18M
Stockholders Equity	-66.18M	-63.61M	-56.48M	-47.76M	-34.09M	-21.45M
Cash Flow
Free Cash Flow	3.96M	-12.00K	-2.30M	-1.52M	-5.10M	-1.33M
Operating Cash Flow	3.97M	-11.00K	-2.29M	-1.50M	-5.07M	-1.25M
Investing Cash Flow	1.58M	2.17M	2.50M	-432.00K	-2.39M	-6.38M
Financing Cash Flow	-3.60M	-1.43M	-1.35M	2.48M	7.23M	7.41M

Emmaus Life Sciences Technical Analysis

Technical Analysis SentimentNegative

Last Price0.02

Price Trends

50DMA0.05Negative

100DMA0.03Negative

200DMA0.02Negative

Market Momentum

MACD-0.01Positive

RSI28.36Positive

STOCH31.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 28.36 is Positive, neither overbought nor oversold. The STOCH value of 31.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EMMA.

Emmaus Life Sciences Risk Analysis

Emmaus Life Sciences disclosed 32 risk factors in its most recent earnings report. Emmaus Life Sciences reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.We have disposed of our former equity interest in EJ Holdings, which may increase the risk that our loans to EJ Holdings will not be repaid.Q4, 2023

2.We may experience difficulties in managing our growth.Q4, 2023

Emmaus Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

EMMA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	40Underperform	$3.26M	-0.19	-189.68%	―	―	83.79%
SCNI	39Underperform	$598.13K	0.00	-23.86%	―	143.06%	94.98%
EMMA	37Underperform	$1.05M	-0.24	9.37%	―	10.98%	-72.08%

* Healthcare Sector Average

Performance Comparison

EMMA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
EMMA	Emmaus Life Sciences Inc	0.02	0.01	130.00%
SCNI	Scinai Immunotherapeutics Ltd. Sponsored Adr	0.40	-9.22	-95.84%
ADTX	Aditxt, Inc.	0.04	-915.80	-100.00%
DRMA	Dermata Therapeutics, Inc.	0.62	-2.22	-78.13%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.06	-86.30%
CDT	Cdt Equity Inc.	0.40	-273949.63	-100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Emmaus Life Sciences AI Stock Analysis